<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kawanabe-Matsuda H</submitter><funding>Japan Agency for Medical Research and Development</funding><funding>Ministry of Education, Culture, Sports, Science and Technology</funding><funding>National Health and Medical Research Council</funding><pagination>1336-1355</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9662940</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(5)</volume><pubmed_abstract>Microbes and their byproducts have been reported to regulate host health and immune functions. Here we demonstrated that microbial exopolysaccharide produced by Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (EPS-R1) induced CCR6+ CD8+ T cells of mice and humans. In mice, ingestion of EPS-R1 augmented antitumor effects of anti-CTLA-4 or anti-PD-1 monoclonal antibody against CCL20-expressing tumors, in which infiltrating CCR6+ CD8+ T cells were increased and produced IFNγ accompanied by a substantial immune response gene expression signature maintaining T-cell functions. Of note, the antitumor adjuvant effect of EPS-R1 was also observed in germ-free mice. Furthermore, the induction of CCR6 expression was mediated through the phosphorylated structure in EPS-R1 and a lysophosphatidic </pubmed_abstract><journal>Cancer discovery</journal><pubmed_title>Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy.</pubmed_title><pmcid>PMC9662940</pmcid><funding_grant_id>1173958 and 1132519</funding_grant_id><funding_grant_id>15K14410</funding_grant_id><funding_grant_id>20gm0010004h9904</funding_grant_id><funding_grant_id>19H03366</funding_grant_id><funding_grant_id>18K19483 and 18H02695</funding_grant_id><pubmed_authors>Okumura K</pubmed_authors><pubmed_authors>Nakamura M</pubmed_authors><pubmed_authors>Kano K</pubmed_authors><pubmed_authors>Eberl G</pubmed_authors><pubmed_authors>Kawanabe-Matsuda H</pubmed_authors><pubmed_authors>Nishimukai M</pubmed_authors><pubmed_authors>Makino S</pubmed_authors><pubmed_authors>Aoki J</pubmed_authors><pubmed_authors>Boneca IG</pubmed_authors><pubmed_authors>Ohno T</pubmed_authors><pubmed_authors>Uwamizu A</pubmed_authors><pubmed_authors>Omi J</pubmed_authors><pubmed_authors>Yagita H</pubmed_authors><pubmed_authors>Takeda K</pubmed_authors><pubmed_authors>Karasaki T</pubmed_authors><pubmed_authors>Kakimi K</pubmed_authors><pubmed_authors>Smyth MJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy.</name><description>Microbes and their byproducts have been reported to regulate host health and immune functions. Here we demonstrated that microbial exopolysaccharide produced by Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (EPS-R1) induced CCR6+ CD8+ T cells of mice and humans. In mice, ingestion of EPS-R1 augmented antitumor effects of anti-CTLA-4 or anti-PD-1 monoclonal antibody against CCL20-expressing tumors, in which infiltrating CCR6+ CD8+ T cells were increased and produced IFNγ accompanied by a substantial immune response gene expression signature maintaining T-cell functions. Of note, the antitumor adjuvant effect of EPS-R1 was also observed in germ-free mice. Furthermore, the induction of CCR6 expression was mediated through the phosphorylated structure in EPS-R1 and a lysophosphatidic </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2026-05-28T22:40:06.819Z</modification><creation>2025-04-04T20:21:48.002Z</creation></dates><accession>S-EPMC9662940</accession><cross_references><pubmed>35180303</pubmed><doi>10.1158/2159-8290.CD-21-0929</doi></cross_references></HashMap>